Publication: Prognostic indicators for heart failure hospitalization in acute coronary syndrome patients: An observational study under the influenza vaccination trial
1
Issued Date
2018-08-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-85052213363
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.101, No.8 (2018), 1043-1049
Suggested Citation
Apirak Sribhutorn, Arintaya Phrommintikul, Wanwarang Wongcharoen, Usa Chaikledkaew, Suntara Eakanunkul, Jayanton Patumanond, Apichard Sukonthasarn Prognostic indicators for heart failure hospitalization in acute coronary syndrome patients: An observational study under the influenza vaccination trial. Journal of the Medical Association of Thailand. Vol.101, No.8 (2018), 1043-1049. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/46476
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Prognostic indicators for heart failure hospitalization in acute coronary syndrome patients: An observational study under the influenza vaccination trial
Abstract
© 2018, Medical Association of Thailand. All rights reserved. Background: Heart failure [HF] is described as a consequence from tissue injury in myocardial infarction through finally organ failure. Therefore, HF prevention through forecasting clinical predictors is useful for closely HF monitoring and management. Objective: To explore prognostic indicators for HF hospitalization in Acute coronary syndrome [ACS] patients through the influenza vaccination trial. Materials and Methods: These observational data were collected from 439 ACS patients of Phrommintikul et al. The inactivated influenza vaccine was injected intramuscularly as a single dose in the vaccination group. The HF hospitalization outcome was determined through one-year follow-up time. The multivariable Cox’s regression model was performed to explore the prognostic values. Results: The significant prognostic indicators were female (HR 4.05, 95% CI 1.25 to 13.19, p = 0.020), dyslipidemia (HR 7.44, 95% CI 1.88 to 29.40, p = 0.004), elevated SCr (HR = 5.46, 95% CI 1.39 to 21.41, p = 0.015), impaired LVEF (HR 9.55, 95% CI 2.55 to 35.81, p = 0.001), and influenza vaccination (HR 0.25, 95% CI 0.07 to 0.86, p = 0.028). Conclusion: ACS patients who were female with dyslipidemia, elevated SCr, and impaired LVEF should be closely monitored for HF. The influenza vaccination had a significant protective effect for HF in ACS. Therefore, the benefit of influenza vaccine should be considered in practice for ACS patients.